Objective: Testing of 38 DPP-related compounds in prion-infected mice to assess therapeutic effects on disease progression and survival
This is a In Vivo Prion Mouse Study protocol using mouse as the model organism. The procedure involves 7 procedural steps, 2 equipment items, 7 materials. Extracted from a 2013 paper published in Acta Neuropathologica.
Model and subjects
mouse • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Initial screening of compound libraries • Identification of initial lead structure • Secondary screening of additional compounds
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Screen two libraries of 10,000 chemically diverse drug-like compounds each (DIVERSet1 and DIVERSet2) for inhibition of prion protein aggregation using molecular SIFT screening assay
Note: Compounds supplied in DMSO solution on 96-well microtiter plates
“we tested a library of 10,000 chemically diverse drug-like compounds in regard to inhibition of prion protein aggregation in a molecular SIFT screening assay”
Based on SIFT screening results combined with testing of primary hits in cellular anti-prion assay, identify N-benzylidene-benzohydrazide (NBB) derivatives as new lead structure with anti-prion activity
Note: NBB compounds also inhibit Poly-Q and α-syn aggregation both in vitro and in vivo, but contain Schiff's base structure prone to rapid metabolism in vivo
“Based on this data in combination with testing of primary hits in a cellular anti-prion assay, we identified N -benzylidene-benzohydrazide (NBB) derivatives as a new lead structure with anti-prion activity”
Screen 10,000 additional compounds and perform parallel analysis of all 20,000 compounds in microtiter plate based high-throughput anti-prion cell culture assay followed by structure-activity and cluster analysis
Note: Analysis identified cluster of highly active compounds belonging to 3,5-diphenyl-pyrazole (DPP) derivatives chemical class
“we continued by screening of 10,000 additional compounds and performed a parallel analysis of all these 20,000 compounds in a microtiter plate based high-throughput anti-prion cell culture assay followed by structure–activity and cluster analysis”
Conduct pilot experiment with one DPP compound from initial screening library in prion-infected mice to assess effect on survival
Note: Pilot experiment showed significant effect on survival in prion-infected mice
“A pilot experiment with one DPP compound from the initial screening library showed a significant effect on survival in prion-infected mice”
Synthesize focused library of approximately 150 DPP-related compounds for further testing in vitro, in cell culture, and in vivo
Note: Details regarding synthesis and quality control provided in supplementary 'Compound Synthesis' section. Materials and solvents purchased from Sigma-Aldrich and Alfa Aesar
“we synthesized a focused library of ~150 DPP-related compounds (Suppl. 'Compound Synthesis') for further testing in vitro, in cell culture, and in vivo”
Based on results from SIFT and cell culture anti-prion assays, select 38 compounds for in vivo testing in prion-infected mice
Note: Selection criteria based on performance in SIFT and cell culture assays
“Based on results from the SIFT and cell culture anti-prion assays, 38 compounds were selected for in vivo testing in prion-infected mice”
Test 38 selected DPP-related compounds in prion-infected mice to assess therapeutic effects on disease progression and survival
Note: anle138b showed highest anti-prion activity and efficacy in in vitro and in vivo models for synucleinopathies
“In these experiments, the compound anle138b [3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1 H -pyrazole] showed the highest anti-prion activity”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
Testing of 38 DPP-related compounds in prion-infected mice to assess therapeutic effects on disease progression and survival
Objective
Testing of 38 DPP-related compounds in prion-infected mice to assess therapeutic effects on disease progression and survival
Subjects
From papermouse • Not specified • unknown • Not specified • Not specified
Cohort notes
From paperPrion-infected mice used for in vivo testing
Initial screening of compound libraries (Not specified)
Identification of initial lead structure (Not specified)
Secondary screening of additional compounds (Not specified)
Pilot in vivo experiment with DPP compound (Not specified)
Inhibition of prion protein aggregation (SIFT assay)
From paperStructure-activity and cluster analysis of compounds tested in SIFT and cell culture anti-prion assays
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Anti-prion activity in cell culture
From paperStructure-activity and cluster analysis of compounds tested in SIFT and cell culture anti-prion assays
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Survival in prion-infected mice
From paperStructure-activity and cluster analysis of compounds tested in SIFT and cell culture anti-prion assays
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Disease progression in prion-infected mice
From paperStructure-activity and cluster analysis of compounds tested in SIFT and cell culture anti-prion assays
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Inhibition of prion protein aggregation (SIFT assay)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Anti-prion activity in cell culture
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Survival in prion-infected mice
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Disease progression in prion-infected mice
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
Structure-activity and cluster analysis of compounds tested in SIFT and cell culture anti-prion assays
Scoring or quantification
Quantify the primary readouts for this experiment: Inhibition of prion protein aggregation (SIFT assay); Anti-prion activity in cell culture; Survival in prion-infected mice; Disease progression in prion-infected mice.
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for Inhibition of prion protein aggregation (SIFT assay), Anti-prion activity in cell culture, Survival in prion-infected mice, Disease progression in prion-infected mice.
Source links and direct wording from the methods section for validation and deeper review.
Citation
Jens Wagner et al. (2013). Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathologica
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
ChemBridge Corp. • Not specified • Not specified • Not specified
ChemBridge Corp. • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Synthesized in-house • Not specified • Not specified • Not specified
Synthesized in-house • Not specified • Not specified • Not specified
Sigma-Aldrich, Germany; Alfa Aesar, Germany • Not specified • Not specified • Not specified
ChemBridge Corp. • Not specified
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
7
Evidence Quotes
16
Protocol Items
9
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
7
Evidence
16
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work